SWOG clinical trial number

SWOG-431

Evaluation of Bis-Chlorethyl-nitrosourea (BCNU) in Multiple Myeloma

Closed

Phase

Accrual

9%

Abbreviated Title

Evaluation of Bis-Chlorethyl-nitrosourea (BCNU) in Multiple Myeloma

Activated

04/16/1969

Research committees

Myeloma

Other Clinical Trials

SWOG Clinical Trial Number

S2213

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Research Committee(s)

Myeloma

Activated

12/01/2023

Accrual

1%

Open

Phase

SWOG Clinical Trial Number

S2209

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance

Research Committee(s)

Myeloma

Activated

05/30/2023

Accrual

10%

Open

Phase

SWOG Clinical Trial Number

S2005

A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)

Research Committee(s)

Myeloma

Activated

06/24/2021

Accrual

10%

Open

Phase